{
    "id": 27459,
    "fullName": "ALK L1198P",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "ALK L1198P lies within the protein kinase domain of the Alk protein (UniProt.org). L1198P is predicted to confer a gain of function on the Alk protein as indicated by increased phosphorylation of Alk and has been demonstrated to confer resistance to Alk inhibitors in the context of EML4-ALK in culture (PMID: 21948233).",
            "references": [
                {
                    "id": 5841,
                    "pubMedId": 21948233,
                    "title": "ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21948233"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 238,
        "geneSymbol": "ALK",
        "terms": [
            "ALK",
            "CD246",
            "NBLST3"
        ]
    },
    "variant": "L1198P",
    "createDate": "01/25/2018",
    "updateDate": "09/06/2018",
    "referenceTranscriptCoordinates": {
        "id": 102062,
        "transcript": "NM_004304",
        "gDna": "chr2:g.29220758A>G",
        "cDna": "c.3593T>C",
        "protein": "p.L1198P",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12753,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells overexpressing ALK L1198P in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 21948233).",
            "molecularProfile": {
                "id": 28912,
                "profileName": "EML4 - ALK ALK L1198P"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5841,
                    "pubMedId": 21948233,
                    "title": "ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21948233"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12754,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells overexpressing ALK L1198P in the context of EML4-ALK were resistant to TAE684 in culture (PMID: 21948233).",
            "molecularProfile": {
                "id": 28912,
                "profileName": "EML4 - ALK ALK L1198P"
            },
            "therapy": {
                "id": 2386,
                "therapyName": "TAE684",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5841,
                    "pubMedId": 21948233,
                    "title": "ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21948233"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12758,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of ALK L1198P in neuroblastoma cells harboring an ALK F1174L mutation resulted in resistance to TAE684 in culture (PMID: 21948233).",
            "molecularProfile": {
                "id": 28913,
                "profileName": "ALK F1174L ALK L1198P"
            },
            "therapy": {
                "id": 2386,
                "therapyName": "TAE684",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5841,
                    "pubMedId": 21948233,
                    "title": "ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21948233"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12756,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of ALK L1198P in neuroblastoma cells harboring an ALK F1174L mutation resulted in resistance to Xalkori (crizotinib) in culture (PMID: 21948233).",
            "molecularProfile": {
                "id": 28913,
                "profileName": "ALK F1174L ALK L1198P"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5841,
                    "pubMedId": 21948233,
                    "title": "ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21948233"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28911,
            "profileName": "ALK L1198P",
            "profileTreatmentApproaches": [
                {
                    "id": 18272,
                    "name": "ALK Inhibitor",
                    "profileName": "ALK L1198P"
                }
            ]
        },
        {
            "id": 28912,
            "profileName": "EML4 - ALK ALK L1198P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28913,
            "profileName": "ALK F1174L ALK L1198P",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 102062,
            "transcript": "NM_004304",
            "gDna": "chr2:g.29220758A>G",
            "cDna": "c.3593T>C",
            "protein": "p.L1198P",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}